Quantum-Si (QSI) Company Report

Quantum-Si Incorporated (QSI) filed an 8-K on December 29, 2025, to furnish its updated corporate presentation to the investment community.
The company reports being well-capitalized with a cash runway into Q2 2028.
Its Proteus platform is on track for launch in Q4 2026.
The Proteus platform is anticipated to provide 40x more sequencing throughput per consumable and feature an estimated 80 million wells at launch, significantly exceeding the Platinum Pro's 2 million wells.

Dec 29, 2025, 9:16 PM

8-K

Quantum-Si Launches New Library Preparation Kit and Data Analysis Tools

QSI

Product Launch

New Projects/Investments

Quantum-Si has launched its Version 3 Library Preparation Kit, which offers a 100-fold improvement in protein input requirements, enabling detection with as little as 1-2 ng of protein.
The company also released data analysis tool enhancements that allow for the detection of an additional amino acid (methionine), expanding total amino acid coverage to 15 with a target of 20 in 2026.
These new offerings are expected to significantly enhance the analysis of scarce biologic samples, complex mixtures, and low abundance biomarkers when combined with the Version 4 Sequencing Kit.

Dec 22, 2025, 1:00 PM

Press Release

Quantum-Si Provides Update on Proteus Platform Development and Financial Position

QSI

Product Launch

New Projects/Investments

Guidance Update

Quantum-Si (QSI) is developing its next-generation protein sequencing platform, Proteus, which features a new architecture designed for significantly higher sequencing output and lower consumable costs compared to its current Platinum instrument.
The company has completed over 50 runs on Proteus prototype systems, achieving a 2025 milestone ahead of schedule, with early data showing performance exceeding the first-generation Platinum machine.
QSI plans to launch Proteus by the end of 2026, with an estimated price point of $300,000-$500,000, and anticipates an early access program by summer 2026.
As of Q3 2025, QSI reported over $230 million in cash, providing a cash runway into Q2 2028, which is approximately 18 months post-Proteus launch.
The company is also making progress on full proteome coverage, aiming to demonstrate all 20 amino acids in 2026 and release a kit in 2027.

Nov 20, 2025, 8:30 PM

Transcript

Quantum-Si Provides Update on Proteus Platform Development and Financial Outlook

QSI

Product Launch

New Projects/Investments

Guidance Update

Quantum-Si's CEO, Jeff Hawkins, highlighted the company's product portfolio, including the Platinum instrument and the upcoming Proteus platform, which features a new architecture designed for significantly higher sequencing output and lower-cost consumables.
The Proteus platform is targeted for launch by the end of 2026, with an early access program planned for summer 2026, and is expected to be priced between $300,000 and $500,000.
Quantum-Si achieved a significant milestone for Proteus by completing over 50 runs on prototype systems, ahead of its 2025 target, with data quality surpassing the current Platinum machine.
The company is leveraging AI tools in its R&D to accelerate full proteome coverage, aiming to demonstrate all 20 amino acids in 2026 and release a corresponding kit in 2027.
Quantum-Si concluded Q3 2025 with over $230 million in cash, projecting a cash runway into Q2 2028, which is approximately 18 months beyond the Proteus launch, and realized savings of over $24 million from exiting a lease.

Nov 20, 2025, 8:30 PM

Transcript

Quantum-Si Provides Update on Proteus Platform Development and Financial Position

QSI

Product Launch

New Projects/Investments

Guidance Update

Quantum-Si (QSI) is developing its next-generation protein sequencing platform, Proteus, which features a new architecture designed for significantly more sequencing output, lower-cost consumables, and greater scalability compared to its current Platinum instrument.
The Proteus platform, announced in November 2024, has already completed over 50 sequencing runs on prototype systems, ahead of its 2025 target. The commercial launch is planned for the end of 2026, with an early access program by Summer 2026.
The anticipated price point for Proteus is between $300,000 and $500,000.
As of Q3 2025, Quantum-Si held over $230 million in cash, providing a cash runway into Q2 2028. The company also realized savings of over $24 million by exiting its New Haven lease.
R&D efforts are progressing, with expectations to increase amino acid coverage to 15 by the end of 2025 and demonstrate all 20 amino acids in 2026, with a kit launch in 2027.

Nov 20, 2025, 8:30 PM

Transcript

Quantum-Si Inc. provides update on Proteus program and 2026 launch timeline

QSI

Product Launch

New Projects/Investments

Quantum-Si Inc. held an Investor & Analyst Day on November 19, 2025, detailing updates on its Proteus program and technology roadmap.
The company anticipates the first integrated Proteus system in Q1 2026 and is targeting a product launch by year-end 2026, with key milestones including instrument list price release in Q2 2026 and external customer collaborations starting in Summer 2026.
Proteus is designed to offer superior sequencing output and quality compared to the Platinum system, with architecture that scales to billions of wells.
Quantum-Si is progressing towards detecting all 20 canonical amino acids in 2026, with release on Proteus in 2027, and is developing comprehensive solutions for Post-translational Modification (PTM) analysis.

Nov 20, 2025, 1:06 PM

8-K

Quantum-Si Details Proteus Platform and Technology Roadmap

QSI

Product Launch

New Projects/Investments

Quantum-Si is transitioning to the Proteus architecture, which significantly scales up well capacity from 2 million to 80 million wells per device, with the architecture supporting billions of wells for future scalability.
The first integrated Proteus systems are expected to be completed in Q1 2026, with a product launch targeted for the end of 2026. At launch, the platform aims to detect 18 amino acids, expanding to the full 20 amino acids in 2027.
The company is prioritizing the development of Post-Translational Modification (PTM) applications on Proteus, with phosphorylation being a high-priority target due to its biological importance and difficulty with current methods.
Quantum-Si is accelerating its recognizer development pipeline by leveraging AI and protein structure prediction methodologies, scaling up the pipeline by approximately 4x.

Nov 19, 2025, 3:00 PM

Transcript

QSI Provides Proteus Program and Technology Roadmap Update

QSI

Product Launch

New Projects/Investments

The Proteus architecture features 80 million wells per device, a significant increase from Platinum's 2 million, and is designed to scale to billions of wells. It offers 1.8 times more alignments per well and a twofold higher pulse signal-to-noise ratio compared to Platinum. The first integrated systems are expected in Q1 2026, with a product launch targeted for the end of 2026.
QSI currently recognizes 14 amino acids with Sequencing Kit V4, and an upcoming software release will enable detection of methionine, bringing the total to 15 amino acids very shortly. The company aims to detect 18 amino acids at the Proteus launch in 2026 and the full 20 amino acids in 2027.
QSI is developing three main approaches for Post-Translational Modification (PTM) detection: kinetics, pre-recognition, and direct detection, aiming for universal access to PTMs. The long-term technology roadmap includes advancements like super Poisson loading and controlled cleavage chemistry to enable scaling to billions of reads with a future Proteus 2.0 instrument.
An upgrade program for existing users is expected to be released in Q3 of 2025.

Nov 19, 2025, 3:00 PM

Transcript

Quantum-Si Reports Q3 2025 Financial Results, Achieves Proteus System Milestone

QSI

Earnings

Product Launch

Guidance Update

Quantum-Si reported Q3 2025 revenue of $552,000 and a gross profit of $194,000, with a gross margin of 35%. Year-to-date Q3 2025 revenue was $2.0 million.
The company successfully completed sequencing runs on a prototype Proteus system, a key 2025 milestone, and commercially launched its Version 4 sequencing kit in early September. The Version 3 library preparation kit is on track for launch by year-end 2025, expected to lower sample input quantity by at least 100-fold.
As of September 30, 2025, Quantum-Si held $230.5 million in cash, cash equivalents, and investments. The company updated its 2025 total cash use guidance to $103 million or less, which includes a $10.2 million net payment for a lease termination expected to save over $24 million in future operating expenses.
Commercial adoption efforts resulted in 12 new customers implementing the platform through expanded acquisition options, with more than half in academic labs.

Nov 5, 2025, 9:30 PM

Transcript

Quantum-Si Reports Q3 2025 Financial Results and Proteus Development Progress

QSI

Earnings

Product Launch

Legal Proceedings

Quantum-Si reported revenue of $552,000 and a net loss of $35.7 million for the third quarter ended September 30, 2025.
Total operating expenses for Q3 2025 were $40.0 million, which included $15.4 million in one-time charges related to settled legacy litigation cases.
As of September 30, 2025, the company held $230.5 million in cash and cash equivalents and investments in marketable securities, projected to fund operations into the second quarter of 2028.
The company announced successful sequencing on a prototype Proteus unit, keeping the Proteus platform launch on track for the second half of 2026, and also launched its version 4 Sequencing Kit in early September 2025.